Stoke Therapeutics, Inc.
STOK· Nasdaq
Released Nov 14, 2022, before the open
10-Q filed Nov 14, 2022, 45 days after period end · 0001564590-22-037497
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $2.91M | — | — | — |
| Net Income | -$26.11M | -$22.60M | -$13.68M | -$8.60M |
| EPS Diluted |
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR
| -$0.66 |
| -$0.60 |
| -$0.41 |
| -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.